JPWO2023211990A5 - - Google Patents

Info

Publication number
JPWO2023211990A5
JPWO2023211990A5 JP2024563159A JP2024563159A JPWO2023211990A5 JP WO2023211990 A5 JPWO2023211990 A5 JP WO2023211990A5 JP 2024563159 A JP2024563159 A JP 2024563159A JP 2024563159 A JP2024563159 A JP 2024563159A JP WO2023211990 A5 JPWO2023211990 A5 JP WO2023211990A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
isomer
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563159A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516005A5 (https=
JP2025516005A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019879 external-priority patent/WO2023211990A1/en
Publication of JP2025516005A publication Critical patent/JP2025516005A/ja
Publication of JPWO2023211990A5 publication Critical patent/JPWO2023211990A5/ja
Publication of JP2025516005A5 publication Critical patent/JP2025516005A5/ja
Pending legal-status Critical Current

Links

JP2024563159A 2022-04-25 2023-04-25 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤 Pending JP2025516005A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202211024240 2022-04-25
IN202211024240 2022-04-25
IN202311013223 2023-02-27
IN202311013223 2023-02-27
PCT/US2023/019879 WO2023211990A1 (en) 2022-04-25 2023-04-25 Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Publications (3)

Publication Number Publication Date
JP2025516005A JP2025516005A (ja) 2025-05-23
JPWO2023211990A5 true JPWO2023211990A5 (https=) 2026-03-17
JP2025516005A5 JP2025516005A5 (https=) 2026-03-17

Family

ID=86469337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563159A Pending JP2025516005A (ja) 2022-04-25 2023-04-25 疼痛の処置のためのnav1.8の二環式複素環アミド阻害剤

Country Status (16)

Country Link
EP (1) EP4514789A1 (https=)
JP (1) JP2025516005A (https=)
KR (1) KR20250006217A (https=)
CN (1) CN119585247A (https=)
AU (1) AU2023263309A1 (https=)
CA (1) CA3256486A1 (https=)
CL (1) CL2024003258A1 (https=)
CO (1) CO2024015763A2 (https=)
CR (1) CR20240512A (https=)
DO (1) DOP2024000215A (https=)
GE (1) GEAP202516637A (https=)
IL (1) IL316433A (https=)
JO (1) JOP20240238A1 (https=)
MX (1) MX2024013065A (https=)
PE (1) PE20251183A1 (https=)
WO (1) WO2023211990A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025529613A (ja) 2022-08-12 2025-09-09 グアンジョウ フェルミオン テクノロジー カンパニー リミテッド 電位開口型ナトリウムチャネル阻害剤としての化合物
WO2025122953A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain
TW202547515A (zh) * 2024-04-30 2025-12-16 大陸商江蘇恆瑞醫藥股份有限公司 芳香環類化合物、其製備方法及其在醫藥上的應用
WO2026001999A1 (zh) * 2024-06-25 2026-01-02 江苏恒瑞医药股份有限公司 芳香环类化合物、其制备方法及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE3211934A1 (de) * 1982-03-31 1983-10-13 Hoechst Ag, 6230 Frankfurt Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU6242096A (en) 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
WO1998027980A2 (en) 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2004034985A2 (en) * 2002-10-16 2004-04-29 Smithkline Beecham Corporation Chemical compounds
ES2377988T3 (es) * 2005-11-14 2012-04-03 Vertex Pharmaceuticals, Inc. Quinazolinas útiles como moduladores de canales iónicos controlados por voltaje
WO2008135830A1 (en) 2007-05-03 2008-11-13 Pfizer Limited N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
AU2014212431B2 (en) 2013-01-31 2018-04-05 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
MA41051B1 (fr) * 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
WO2019157505A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2020261114A1 (en) 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
BR112022024476A2 (pt) 2020-06-17 2022-12-27 Merck Sharp & Dohme Llc 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
GEP20257750B (en) 2020-06-17 2025-03-25 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
WO2022121805A1 (zh) * 2020-12-07 2022-06-16 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途

Similar Documents

Publication Publication Date Title
TWI436986B (zh) 新穎之2環性雜環化合物
TWI487701B (zh) 作為蛋白質激酶抑制劑之化合物及組合物
JP6134046B1 (ja) 医療で使用されるインドール誘導体
TWI500616B (zh) 新穎之雙環吡啶酮
US20140343084A1 (en) Imidazopyrrolidinone compounds
JPWO2022014639A5 (https=)
JP2013542256A5 (https=)
JP2005536475A5 (https=)
KR20170081204A (ko) 제약 화합물
RU2009147708A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
CN1561393A (zh) 用于治疗青光眼的糖原合成酶激酶-3(gsk-3)的抑制剂
JP2015503507A5 (https=)
CN101678107A (zh) 用于治疗杜兴型肌营养不良的药物组合物
JP2011509309A5 (https=)
JP2011042668A5 (https=)
JP2006501201A5 (https=)
JP2016503797A5 (https=)
CN112654349A (zh) PIKfyve抑制剂
EA037587B1 (ru) Способ получения противогрибковых соединений
TW201636339A (zh) 作爲磷脂醯肌醇3-激酶δ抑制劑的取代嘧啶類化合物及其應用
MA30704B1 (fr) Compositions therapeutiques
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
KR950701323A (ko) 1-피페라지노-1,2-디히드로인덴 유도체(1-Piperazino-1,2-dihydroindene Derivatives)
JP2010529969A5 (https=)
US20240390399A1 (en) Materials and methods for suppressing and/or treating bone related diseases and symptoms